ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids

SIMPLE SUMMARY: Ovarian cancer (OvCa) treatment is still a challenge, mainly due to acquired resistance mechanisms during the course of chemotherapy. Here, we show the enhanced cytotoxicity of the combined treatment with the ADAM17 inhibitor GW280264X and cisplatin in comparison with cisplatin monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedemann, Nina, Herz, Andreas, Schiepanski, Jan Hendrik, Dittrich, Jan, Sebens, Susanne, Dempfle, Astrid, Feuerborn, Julia, Rogmans, Christoph, Tribian, Nils, Flörkemeier, Inken, Weimer, Jörg, Krüger, Sandra, Maass, Nicolai, Bauerschlag, Dirk O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122950/
https://www.ncbi.nlm.nih.gov/pubmed/33922533
http://dx.doi.org/10.3390/cancers13092039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122950/
https://www.ncbi.nlm.nih.gov/pubmed/33922533
http://dx.doi.org/10.3390/cancers13092039

Ejemplares similares